Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication? (original) (raw)

Effect of desipramine, fluoxetine and tranylcypromine on viability and apoptosis of rat primary neuronal and astrocytic cell cultures subjected to oxygen-glucose deprivation in vitro

Anna Pudelko

Pharmacological Reports, 2015

View PDFchevron_right

Antidepressant treatment influences group I of glutamate metabotropic receptors in slices from hippocampal CA1 region

Andrzej Pilc

European Journal of Pharmacology, 1998

View PDFchevron_right

Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus

Andrea Caricasole

Neuropharmacology, 2002

View PDFchevron_right

Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex

Andrzej Pilc

Brain Research, 2007

View PDFchevron_right

Metabotropic glutamate receptors and neuroadaptation to antidepressants: imipramine-induced down-regulation of β-adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands

Daniela Melchiorri

Journal of Neurochemistry, 2005

View PDFchevron_right

Comparative Effects of LY3020371, a Potent and Selective mGlu2/3 Receptor Antagonist, and Ketamine, a Non-Competitive NMDA Receptor Antagonist, in Rodents: Evidence Supporting Use for the Treatment of Depression

Jeffrey Witkin

The Journal of pharmacology and experimental therapeutics, 2017

View PDFchevron_right

mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants

Yukio Ago

Neuropharmacology, 2013

View PDFchevron_right

Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression

Craig Stockmeier, Jose J A V I E R Miguel-Hidalgo

Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010

View PDFchevron_right

Chronic imipramine treatment reduces inhibitory properties of group II mGlu receptors without affecting their density or affinity

Piotr Brański

Pharmacological reports : PR

View PDFchevron_right

On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039

Andrzej Pilc

Psychopharmacology, 2010

View PDFchevron_right

Is the mGlu5 receptor a possible target for new antidepressant drugs?

Andrzej Pilc

Pharmacological Reports, 2013

View PDFchevron_right

Increase in neurogenesis and behavioural benefit after chronic fluoxetine treatment in Wistar rats

Anders Klein

Acta Neurologica Scandinavica, 2007

View PDFchevron_right

GluN2B-containing NMDA receptors as possible targets for the neuroprotective and antidepressant effects of fluoxetine

Dalma Kurko

Neurochemistry International, 2012

View PDFchevron_right

Modulation of glutamate receptors: Strategies for the development of novel antidepressants

Phil Skolnick

Amino Acids, 2002

View PDFchevron_right

The Action of Antidepressants on the Glutamate System: Regulation of Glutamate Release and Glutamate Receptors

Laura Musazzi

Biological Psychiatry, 2013

View PDFchevron_right

On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants

Andrzej Pilc

Polish journal of pharmacology

View PDFchevron_right

Group III metabotropic glutamate receptor-mediated, chemically induced long-term depression differentially affects cell viability in the hippocampus

Denise Manahan-Vaughan

European Journal of Pharmacology, 2006

View PDFchevron_right

Antidepressant fluoxetine suppresses neuronal growth from both vertebrate and invertebrate neurons and perturbs synapse formation between Lymnaea neurons

Fenglian Xu, Wali Zaidi, Naweed Syed

European Journal of Neuroscience, 2010

View PDFchevron_right

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

James Monn

Psychopharmacology, 2007

View PDFchevron_right

Neurogenesis-Dependent and Independent Effects of Fluoxetine in an Animal Model of Anxiety/Depression

bruno guiard

Neuron, 2009

View PDFchevron_right

A characterisation of long-term depression induced by metabotropic glutamate receptor activation in the rat hippocampus in vitro

Graham Collingridge

The Journal of Physiology, 2001

View PDFchevron_right

Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Reduces Nigrostriatal Degeneration in Mice Treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine

Valeria Flowhara Bruno

The Journal of Neuroscience, 2006

View PDFchevron_right

Glutamate-Based Antidepressants: Preclinical Psychopharmacology

Phil Skolnick, Andrzej Pilc

Biological Psychiatry, 2013

View PDFchevron_right

Antidepressant action: to the nucleus and beyond

Jessica Malberg

Trends in Pharmacological Sciences, 2005

View PDFchevron_right

Behavioral Effects of Fluoxetine in an Animal Model of Anxiety/Depression Are Mediated by Both Neurogenesis-Dependent and Independent Mechanisms

bruno guiard

View PDFchevron_right

Activation of the mGlu7 receptor elicits antidepressant-like effects in mice

Herman Van Der Putten, Andrzej Pilc

Psychopharmacology, 2007

View PDFchevron_right

Prolonged administration of antidepressant drugs leads to increased binding of [3H]MPEP to mGlu5 receptors

Andrzej Pilc

Neuropharmacology, 2014

View PDFchevron_right

Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039)

Kjell Svensson

Journal of Pharmacology and Experimental Therapeutics, 2008

View PDFchevron_right